Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab versus placebo for moderate to severe hidradenitis suppurativa
NL-OMON51225Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of spesolimab in hidradenitis suppurativa (HS), sponsored by Boehringer Ingelheim. Primary endpoint: Percent change from baseline in total abscess and inflammatory nodule count at Week 12. Started Aug 2021; status: active, not recruiting.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON51225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51225.